Risk Factors for Detectable HIV-1 RNA at Delivery Among Women Receiving Highly Active Antiretroviral Therapy in the Women and Infants Transmission Study

Background:Detectable HIV-1 RNA at delivery is the strongest predictor of mother-to-child transmission. The risk factors for detectable HIV, including type of regimen, are unknown. We evaluated factors, including highly active antiretroviral (HAART) regimen, associated with detectable HIV-1 RNA at delivery in the Women and Infants Transmission Study (WITS). Methods:Data from 630 HIV-1-infected women who enrolled from 1998 to 2005 and received HAART during pregnancy were analyzed. Multivariable analyses examined associations between regimens, demographic factors, and detectable HIV-1 RNA (>400 copies/milliliter) at delivery. Results:Overall, 32% of the women in the cohort had detectable HIV-1 RNA at delivery. Among the subset of 364 HAART-experienced women, a lower CD4+ cell count at enrollment [adjusted odds ratio (AOR) = 1.20 per 100 cells/μL, confidence interval (CI) 1.04 to 1.37] and higher HIV-1 RNA at enrollment (AOR = 1.52 per log10 copies/milliliter, CI 1.32 to 1.75) were significantly associated with detectable HIV-1 RNA levels at delivery. For the 266 HAART-naive women, both lower CD4+ cell count at enrollment (AOR = 1.24 per 100 cells/μL, CI 1.05 to 1.48) and higher HIV-1 RNA at enrollment (AOR = 1.35 per log10 copies/milliliter, CI 1.12 to 1.63) were associated with detectable HIV-1 RNA at delivery. In addition, age at delivery (AOR = 0.92 per 10 years older, CI 0.86 to 0.99) and maternal illicit drug use (AOR = 3.15, CI 1.34 to 7.41) were significantly associated with detectable HIV-1 RNA at delivery among HAART-naive women. Type of HAART regimen was not significant in either group. Conclusions:Lack of viral suppression at delivery was common in the WITS cohort, but differences by antiretroviral regimen were not identified. Despite a transmission rate below 1% in the last 5 years of the WITS cohort, improved measures to maximize HIV-1 RNA suppression at term among high-risk women are warranted.

[1]  A. Stek.  Antiretroviral medications during pregnancy for therapy or prophylaxis , 2009, Current HIV/AIDS reports.

[2]  V. Soriano,et al.  [Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy]. , 2009, Medicina clinica.

[3]  Chengcheng Hu,et al.  Lopinavir Exposure With an Increased Dose During Pregnancy , 2008, Journal of acquired immune deficiency syndromes.

[4]  M. Mirochnick,et al.  Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum , 2008, HIV medicine.

[5]  C. Zorrilla,et al.  Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women , 2008, AIDS care.

[6]  M. Cortina-Borja,et al.  Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  T. Cressey,et al.  Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. , 2007, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[8]  Chengcheng Hu,et al.  Reduced lopinavir exposure during pregnancy , 2006, AIDS.

[9]  R. Elston,et al.  Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy: A Systematic Overview , 2006, Journal of acquired immune deficiency syndromes.

[10]  W. Blattner,et al.  Risk Factors for In Utero and Intrapartum Transmission of HIV , 2005, Journal of acquired immune deficiency syndromes.

[11]  R. Clark.  Sex Differences in Antiretroviral Therapy-Associated Intolerance and Adverse Events , 2005, Drug safety.

[12]  L. Mofenson.  Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States , 2003 .

[13]  W. Blattner,et al.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. , 2002 .

[14]  L. Kalish,et al.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. , 1999, The New England journal of medicine.

[15]  D. Harris,et al.  RISK FACTORS FOR PERINATAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN WOMEN TREATED WITH ZIDOVUDINE , 1999 .

[16]  M. Kalish,et al.  The effect of maternal viral load on the risk of perinatal transmission of HIV‐1 , 1997, AIDS.

[17]  P. Stratton,et al.  The Women and Infants Transmission Study (WITS) of Maternal-Infant HIV Transmission: Study Design, Methods, and Baseline Data , 1996 .

[18]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.